IBDEI14H ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20036,1,4,0)
 ;;=4^HOMELESS
 ;;^UTILITY(U,$J,358.3,20036,2)
 ;;=^295539
 ;;^UTILITY(U,$J,358.3,20037,0)
 ;;=V65.19^^112^1204^17
 ;;^UTILITY(U,$J,358.3,20037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20037,1,3,0)
 ;;=3^V65.19
 ;;^UTILITY(U,$J,358.3,20037,1,4,0)
 ;;=4^PERS. CONS FOR ANOTHER
 ;;^UTILITY(U,$J,358.3,20037,2)
 ;;=^329985
 ;;^UTILITY(U,$J,358.3,20038,0)
 ;;=V72.5^^112^1204^20
 ;;^UTILITY(U,$J,358.3,20038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20038,1,3,0)
 ;;=3^V72.5
 ;;^UTILITY(U,$J,358.3,20038,1,4,0)
 ;;=4^RADIOLOGICAL EXAM NEC
 ;;^UTILITY(U,$J,358.3,20038,2)
 ;;=^276359
 ;;^UTILITY(U,$J,358.3,20039,0)
 ;;=V81.2^^112^1204^24
 ;;^UTILITY(U,$J,358.3,20039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20039,1,3,0)
 ;;=3^V81.2
 ;;^UTILITY(U,$J,358.3,20039,1,4,0)
 ;;=4^SCREEN-CARDIOVASC NEC
 ;;^UTILITY(U,$J,358.3,20039,2)
 ;;=^295689
 ;;^UTILITY(U,$J,358.3,20040,0)
 ;;=V77.1^^112^1204^25
 ;;^UTILITY(U,$J,358.3,20040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20040,1,3,0)
 ;;=3^V77.1
 ;;^UTILITY(U,$J,358.3,20040,1,4,0)
 ;;=4^SCREEN-DIABETES MELLITUS
 ;;^UTILITY(U,$J,358.3,20040,2)
 ;;=^295662
 ;;^UTILITY(U,$J,358.3,20041,0)
 ;;=V80.3^^112^1204^26
 ;;^UTILITY(U,$J,358.3,20041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20041,1,3,0)
 ;;=3^V80.3
 ;;^UTILITY(U,$J,358.3,20041,1,4,0)
 ;;=4^SCREEN-EAR DISEASE
 ;;^UTILITY(U,$J,358.3,20041,2)
 ;;=^295686
 ;;^UTILITY(U,$J,358.3,20042,0)
 ;;=V77.91^^112^1204^28
 ;;^UTILITY(U,$J,358.3,20042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20042,1,3,0)
 ;;=3^V77.91
 ;;^UTILITY(U,$J,358.3,20042,1,4,0)
 ;;=4^SCREEN-LIPOID DISORDERS
 ;;^UTILITY(U,$J,358.3,20042,2)
 ;;=^322093
 ;;^UTILITY(U,$J,358.3,20043,0)
 ;;=V82.0^^112^1204^30
 ;;^UTILITY(U,$J,358.3,20043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20043,1,3,0)
 ;;=3^V82.0
 ;;^UTILITY(U,$J,358.3,20043,1,4,0)
 ;;=4^SCREEN-SKIN DISEASE
 ;;^UTILITY(U,$J,358.3,20043,2)
 ;;=^295694
 ;;^UTILITY(U,$J,358.3,20044,0)
 ;;=V74.1^^112^1204^31
 ;;^UTILITY(U,$J,358.3,20044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20044,1,3,0)
 ;;=3^V74.1
 ;;^UTILITY(U,$J,358.3,20044,1,4,0)
 ;;=4^SCREEN-TB
 ;;^UTILITY(U,$J,358.3,20044,2)
 ;;=^108715
 ;;^UTILITY(U,$J,358.3,20045,0)
 ;;=V82.89^^112^1204^29
 ;;^UTILITY(U,$J,358.3,20045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20045,1,3,0)
 ;;=3^V82.89
 ;;^UTILITY(U,$J,358.3,20045,1,4,0)
 ;;=4^SCREEN-OTH SPECIFIED CONDITIONS
 ;;^UTILITY(U,$J,358.3,20045,2)
 ;;=^322099
 ;;^UTILITY(U,$J,358.3,20046,0)
 ;;=V81.1^^112^1204^27
 ;;^UTILITY(U,$J,358.3,20046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20046,1,3,0)
 ;;=3^V81.1
 ;;^UTILITY(U,$J,358.3,20046,1,4,0)
 ;;=4^SCREEN-HYPERTENSION
 ;;^UTILITY(U,$J,358.3,20046,2)
 ;;=^295688
 ;;^UTILITY(U,$J,358.3,20047,0)
 ;;=V68.81^^112^1204^21
 ;;^UTILITY(U,$J,358.3,20047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20047,1,3,0)
 ;;=3^V68.81
 ;;^UTILITY(U,$J,358.3,20047,1,4,0)
 ;;=4^REFERRAL-NO EXAM/TREAT
 ;;^UTILITY(U,$J,358.3,20047,2)
 ;;=^295587
 ;;^UTILITY(U,$J,358.3,20048,0)
 ;;=V72.83^^112^1204^19
 ;;^UTILITY(U,$J,358.3,20048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20048,1,3,0)
 ;;=3^V72.83
 ;;^UTILITY(U,$J,358.3,20048,1,4,0)
 ;;=4^PRE-OP EXAM,OTH SPECIFIED
 ;;^UTILITY(U,$J,358.3,20048,2)
 ;;=^321505
 ;;^UTILITY(U,$J,358.3,20049,0)
 ;;=V65.40^^112^1204^14
 ;;^UTILITY(U,$J,358.3,20049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20049,1,3,0)
 ;;=3^V65.40
 ;;^UTILITY(U,$J,358.3,20049,1,4,0)
 ;;=4^COUNSELING NEC
 ;;^UTILITY(U,$J,358.3,20049,2)
 ;;=^87449
 ;;^UTILITY(U,$J,358.3,20050,0)
 ;;=V68.9^^112^1204^1
